Key result
Advanced age (≥75 years) was associated with significantly decreased clopidogrel-mediated platelet inhibition compared to younger patients (P≤0.004 for P-selectin and GPIIb/IIIa).
Why the study?
Does patient age affect platelet inhibition by clopidogrel in patients on dual antiplatelet therapy after angioplasty and stenting?
Cross-Sectional (n=302)
Does patient age affect platelet inhibition by clopidogrel in patients on dual antiplatelet therapy after angioplasty and stenting?
p-value: p=<0.05
The antiplatelet efficacy of clopidogrel is significantly reduced in older patients (≥75 years), suggesting age-dependent variability in platelet inhibition.
No takes yet. Share an insight, caveat, or question.
May warrant platelet function monitoring in elderly post-stent patients; leaves open whether age-specific regimens improve outcomes.
Xhelili et al. (2016) conducted a cross-sectional in Post-angioplasty and stenting on dual antiplatelet therapy (n=302). Advanced age (≥75 years) vs. Younger patients (<75 years) was evaluated on ADP-inducible P-selectin expression, activated GPIIb/IIIa, and monocyte-platelet aggregate (MPA) formation (p=<0.05). Advanced age (≥75 years) was associated with significantly decreased clopidogrel-mediated platelet inhibition compared to younger patients (P≤0.004 for P-selectin and GPIIb/IIIa).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: